3-(2-formylaminophenyl)-3-oxopropionic acid | 59019-36-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(2-formylaminophenyl)-3-oxopropionic acid
• 英文别名: 3-(2-formylamino-phenyl)-3-oxo-propionic acid；3-(2-Formylamino-phenyl)-3-oxo-propionsaeure；2-Formaminobenzoylacetate；3-(2-formamidophenyl)-3-oxopropanoic acid
• CAS: 59019-36-2
• 化学式: C₁₀H₉NO₄
• 分子量: 207.186
• InChiKey: ZGQVEYFFYPOUKD-UHFFFAOYSA-N

物化性质

• 沸点：
  525.5±35.0 °C(Predicted)
• 密度：
  1.391±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-formylaminophenyl)-3-oxopropionic acid 在 盐酸 、 碳酸氢钠 作用下， 生成 2,4-喹啉二醇
  参考文献：
  名称：

  Schoepf et al., Chemische Berichte, 1956, vol. 89, p. 2877,2885

  摘要：

  DOI：
• 作为产物：
  描述：

  3-吲哚乙酸 在 palladium on activated charcoal 臭氧 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 以33%的产率得到3-(2-formylaminophenyl)-3-oxopropionic acid
  参考文献：
  名称：

  “Untypical Aging Off-Flavor” in Wine:  Synthesis of Potential Degradation Compounds of Indole-3-acetic Acid and Kynurenine and Their Evaluation as Precursors of 2-Aminoacetophenone

  摘要：

  Kynurenine (1) and indole-3-acetic acid (2) are considered as potential precursors of 2-amino-acetophenone (3), which is regarded to be the aroma impact compound causing an "untypical aging off-flavor" (UTA) in Vitis vinifera wines. The mechanism of the formation of 3 was studied using model fermentation and model sulfuration media spiked with 1 or 2 as potential precursors. Possible degradation products such as kynurenamine (4) and kynurenic acid (5), or skatole (6), 2-oxoskatole (7), 2-formamidoacetophenone (8), 2-oxindole-3-acetic acid (9), and 3-(2-formylaminophenyl)-3-oxopropionic acid (10) were evaluated by HPLC-UV of the fermentation and sulfuration media and comparison with synthesized 7, 8, 9, and 10. The synthesis of the possible precursor 4-(2-aminophenyl)-2,4-dioxobutanoic acid (111), a proposed metabolite of 1 failed because a spontaneous cyclization yields 5 and N-oxo-kynurenic acid (12), but not 11. It could be shown that the formation of 3 is triggered by an oxidative degradation of 2 after sulfuration with potassium bisulfite via the intermediates 10 and 8. However, no formation of 3 occurred during sulfuration of a model wine spiked with 1 or during fermentation of a model must spiked with 1 or 2.

  DOI：

  10.1021/jf011672r

文献信息

• COMPOSITION COMPRISING INTERFERON GAMMA AND AN HDAC INHIBITOR OR GONADOTROPIN RECEPTOR SIGNALLING HORMONE
  申请人：Idogen AB

  公开号：EP3238726A2

  公开（公告）日：2017-11-01

  The invention relates to the use of a composition comprising at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein said inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.

  本发明涉及一种包含至少两种化合物（每种化合物都能诱导吲哚胺-2,3-二氧 化酶）的组合物，用于治疗自身免疫紊乱或疾病或移植或基因治疗修饰细胞的免疫排斥反应，其中所述诱导剂具有不同的作用机制，并且该组合物对 IDO 水平具有协同作用。
• THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS
  申请人：Idogen AB

  公开号：EP2164500A1

  公开（公告）日：2010-03-24
• A COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3-DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR SUFFERING FROM IMMUNE REJECTION OF ORGANS
  申请人：Idogen AB

  公开号：EP2654758A1

  公开（公告）日：2013-10-30
• A COMPOSITION COMPRISING AT LEAST TWO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3-DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR IMMUNE REJECTION OF ORGANS
  申请人：Idogen AB

  公开号：EP2654758B1

  公开（公告）日：2017-04-19
• USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS
  申请人：Salford Leif G.

  公开号：US20110300142A1

  公开（公告）日：2011-12-08

  The invention relates to the use of 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.